Abstract
DNA methyltransferase 3A (DNMT3A) catalyzes cytosine methylation of mammalian genomic DNA. In addition to myeloid malignancies, mutations in DNMT3A have been recently reported in T-cell lymphoma and leukemia, implying a possible involvement in the pathogenesis of human diseases. However, the role of Dnmt3a in T-cell transformation in vivo is poorly understood. Here we analyzed the functional consequences of Dnmt3a inactivation in a mouse model of MYC-induced T-cell lymphomagenesis (MTCL). Loss of Dnmt3a delayed tumorigenesis by suppressing cellular proliferation during disease progression. Gene expression profiling and pathway analysis identified upregulation of 17 putative tumor suppressor genes, including DNA methyltransferase Dnmt3b, in Dnmt3a-deficient lymphomas as molecular events potentially responsible for the delayed lymphomagenesis in Dnmt3aΔ/Δ mice. Interestingly, promoter and gene body methylation of these genes was not substantially changed between control and Dnmt3a-deficient lymphomas, suggesting that Dnmt3a may inhibit their expression in a methylation-independent manner. Re-expression of both wild type and catalytically inactive Dnmt3a in Dnmt3aΔ/Δ lymphoma cells in vitro inhibited Dnmt3b expression, indicating that Dnmt3b upregulation may be directly repressed by Dnmt3a. Importantly, genetic inactivation of Dnmt3b accelerated lymphomagenesis in Dnmt3aΔ/Δ mice, demonstrating that upregulation of Dnmt3b is a relevant molecular change in Dnmt3a-deficient lymphomas that inhibits disease progression. Collectively, our data demonstrate an unexpected oncogenic role for Dnmt3a in MTCL through methylation-independent repression of Dnmt3b and possibly other tumor suppressor genes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Fernandez AF, Huidobro C, Fraga MF . De novo DNA methyltransferases: oncogenes, tumor suppressors, or both? Trends Genet 2012; 28: 474–479.
Pradhan S, Bacolla A, Wells RD, Roberts RJ . Recombinant human DNA (cytosine-5) methyltransferase. I. Expression, purification, and comparison of de novo and maintenance methylation. J Biol Chem 1999; 274: 33002–33010.
Li E, Bestor TH, Jaenisch R . Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992; 69: 915–926.
Okano M, Bell DW, Haber DA, Li E . DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999; 99: 247–257.
Borgel J, Guibert S, Li Y, Chiba H, Schübeler D, Sasaki H et al. Targets and dynamics of promoter DNA methylation during early mouse development. Nat Genet 2010; 42: 1093–1100.
Fuks F, Burgers WA, Godin N, Kasai M, Kouzarides T . Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J. 2001; 20: 2536–2544.
Datta J, Majumder S, Bai S, Ghoshal K, Kutay H, Smith DS et al. Physical and functional interaction of DNA methyltransferase 3A with Mbd3 and Brg1 in mouse lymphosarcoma cells. Cancer Res. 2005; 65: 10891–10900.
Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011; 25: 1153–1158.
Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 2014; 123: 1293–1296.
Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 2424–2433.
Neumann M, Heesch S, Schlee C, Schwartz S, Gökbuget N, Hoelzer D et al. Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. Blood 2013; 121: 4749–4752.
Couronné L, Bastard C, Bernard OA . TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med 2012; 366: 95–96.
Kim SJ, Zhao H, Hardikar S, Singh AK, Goodell MA, Chen T . A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells. Blood 2013; 122: 4086–4089.
Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai C et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 2006; 20: 2096–2109.
Thorns C, Bastian B, Pinkel D, Roydasgupta R, Fridlyand J, Merz H et al. Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: A matrix-based CGH approach. Genes Chromosomes Cancer 2007; 46: 37–44.
Felsher DW, Bishop JM . Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999; 4: 199–207.
Peters SL, Hlady RA, Opavska J, Klinkebiel D, Novakova S, Smith LM et al. Essential role for Dnmt1 in the prevention and maintenance of MYC-induced T-cell lymphomas. Mol Cell Biol 2013; 33: 4321–4333.
Hlady RA, Novakova S, Opavska J, Klinkebiel D, Peters SL, Bies J et al. Loss of Dnmt3b function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesis. J Clin Invest 2012; 122: 163–177.
Peters SL, Hlady RA, Opavska J, Klinkebiel D, Pirruccello SJ, Talmon GA et al. Tumor suppressor functions of Dnmt3a and Dnmt3b in the prevention of malignant mouse lymphopoiesis. Leukemia 2014; 28: 1138–1142.
Ball MP, Li JB, Gao Y, Lee JH, LeProust EM, Park IH et al. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol 2009; 27: 361–368.
Wu H, Coskun V, Tao J, Xie W, Ge W, Yoshikawa K et al. Dnmt3a-dependent nonpromoter DNA methylation facilitates transcription of neurogenic genes. Science 2010; 329: 444–448.
Russler-Germain DA, Spencer DH, Young MA, Lamprecht TL, Miller CA, Fulton R et al. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell 2014; 25: 442–454.
Connor F, Bertwistle D, Mee PJ, Ross GM, Swift S, Grigorieva E et al. Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. Nat Genet 1997; 17: 423–430.
Lin W, Sampathi S, Dai H, Liu C, Zhou M, Hu J et al. Mammalian DNA2 helicase/nuclease cleaves G-quadruplex DNA and is required for telomere integrity. EMBO J 2013; 32: 1425–1439.
Schaetzlein S, Chahwan R, Avdievich E, Roa S, Wei K, Eoff RL et al. Mammalian Exo1 encodes both structural and catalytic functions that play distinct roles in essential biological processes. Proc Natl Acad Sci USA 2013; 110: 2470–2479.
Steele-Perkins G, Fang W, Yang XH, Van Gele M, Carling T, Gu J et al. Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein-methyltransferase superfamily. Genes Dev 2001; 15: 2250–2262.
Ramkumar C, Kong Y, Cui H, Hao S, Jones SN, Gerstein RM et al. Smurf2 regulates the senescence response and suppresses tumorigenesis in mice. Cancer Res 2012; 72: 2714–2719.
Wang Y, Klumpp S, Amin HM, Liang H, Li J, Estrov Z et al. SSBP2 is an in vivo tumor suppressor and regulator of LDB1 stability. Oncogene 2010; 29: 3044–3053.
Shang Q, Zhang D, Guo C, Lin Q, Guo Z, Deng C . Potential synergism of Bim with p53 in mice with Myc-induced lymphoma in a mouse lymphoma model. Mol Med Rep 2012; 5: 1401–1408.
Baudino TA, Maclean KH, Brennan J, Parganas E, Yang C, Aslanian A et al. Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss. Mol Cell 2003; 11: 905–914.
Orii KE, Lee Y, Kondo N, McKinnon PJ . Selective utilization of nonhomologous end-joining and homologous recombination DNA repair pathways during nervous system development. Proc Natl Acad Sci USA 2006; 103: 10017–10022.
Mann MB, Hodges CA, Barnes E, Vogel H, Hassold TJ, Luo G et al. Defective sister-chromatid cohesion, aneuploidy and cancer predisposition in a mouse model of type II Rothmund-Thomson syndrome. Hum Mol Genet 2005; 14: 813–825.
Schuster C, Berger A, Hoelzl MA, Putz EM, Frenzel A, Simma O et al. The cooperating mutation or "second hit" determines the immunologic visibility toward MYC-induced murine lymphomas. Blood 2011; 118: 4635–4645.
Opavsky R, Wang SH, Trikha P, Raval A, Huang Y, Wu YZ et al. CpG island methylation in a mouse model of lymphoma is driven by the genetic configuration of tumor cells. PLoS Gene 2007; 3: 1757–1769.
Opavsky R, Tsai SY, Guimond M, Arora A, Opavska J, Becknell B et al. Specific tumor suppressor function for E2F2 in Myc-induced T-cell lymphomagenesis. Proc Natl Acad Sci USA 2007; 104: 15400–15405.
Iskander K, Barrios RJ, Jaiswal AK . Disruption of NAD(P)H:quinone oxidoreductase 1 gene in mice leads to radiation induced myeloproliferative disease. Cancer Res 2008; 68: 7915–7922.
Liu J, Xiang Z, Ma X . Role of IFN regulatory factor-1 and IL-12 in immunological resistance to pathogenesis of N-methyl-N-nitrosourea-induced T lymphoma. J Immunol 2004; 173: 1184–1193.
Li H, Kaminski MS, Li Y, Yildiz M, Ouillette P, Jones S et al. Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. Blood 2014; 123: 1487–1498.
Kulis M, Heath S, Bibikova M, Queirós AC, Navarro A, Clot G et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet 2011; 44: 1236–1242.
Palamarchuk A, Yan PS, Zanesi N, Wang L, Rodrigues B, Murphy M et al. Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci USA 2012; 109: 2555–2560.
Gao Q, Steine EJ, Barrasa MI, Hockemeyer D, Pawlak M, Fu D et al. Deletion of the de novo DNA methyltransferase Dnmt3a promotes lung tumor progression. Proc Natl Acad Sci USA 2011; 108: 18061–18066.
Weis B, Schmidt J, Maamar H, Raj A, Lin H, Tóth C et al. Inhibition of intestinal tumor formation by deletion of the DNA methyltransferase 3a. Oncogene; e-pub ahead of print 19 May 2014; doi:10.1038/onc.2014.114.
Vasanthakumar A, Lepore JB, Zegarek MH, Kocherginsky M, Singh M, Davis EM et al. Dnmt3b is a haploinsufficient tumor suppressor gene in Myc-induced lymphomagenesis. Blood 2013; 121: 2059–2063.
Challen GA, Sun D, Jeong M, Luo M, Jelinek J, Berg JS et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 2011; 44: 23–31.
Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL, Wolffe AP . DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet 2000; 25: 338–342.
Puto LA, Reed JC . Daxx represses RelB target promoters via DNA methyltransferase recruitment and DNA hypermethylation. Genes Dev 2008; 22: 998–1010.
Hervouet E, Vallette FM, Cartron PF . Dnmt3/transcription factor interactions as crucial players in targeted DNA methylation. Epigenetics 2009; 4: 487–499.
Wang YA, Kamarova Y, Shen KC, Jiang Z, Hahn MJ, Wang Y et al. DNA methyltransferase-3a interacts with p53 and represses p53-mediated gene expression. Cancer Biol Ther 2005; 4: 1138–1143.
Li H, Rauch T, Chen ZX, Szabó PE, Riggs AD, Pfeifer GP . The histone methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly and localize to promoters silenced in cancer cells. J Biol Chem 2006; 281: 19489–19500.
Robinson MD, McCarthy DJ, Smyth GK . edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010; 26: 139–140.
Robinson MD, Smyth GK . Moderated statistical tests for assessing differences in tag abundance. Bioinformatics 2007; 23: 2881–2887.
Baldi P, Long AD . A Bayesian framework for the analysis of microarray expression data: regularized t-test and statistical inferences of gene changes. Bioinformatics 2001; 17: 509–519.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Oncogene website
Rights and permissions
About this article
Cite this article
Haney, S., Hlady, R., Opavska, J. et al. Methylation-independent repression of Dnmt3b contributes to oncogenic activity of Dnmt3a in mouse MYC-induced T-cell lymphomagenesis. Oncogene 34, 5436–5446 (2015). https://doi.org/10.1038/onc.2014.472
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2014.472
This article is cited by
-
Loss of Dnmt3a induces CLL and PTCL with distinct methylomes and transcriptomes in mice
Scientific Reports (2016)